Routes to European Commercialisation in Europe

Title: Routes to Commercialisation in Europe Author: Anna Casse, Managing Partner Abstract In the past it was not extraordinary for US biotech companies to develop drugs in the US and to launch them...
Learn More

Agencies Clarify NASH Endpoints—But Don’t Harmonize

Title: Agencies Clarify NASH Endpoints—But Don’t Harmonize Author: Peter G. Traber, MD The FDA and EMA have recently published very similar clinical trial endpoints for pre-cirrhotic NASH, with one...
Learn More

Industry Strategies for NASH Combination Therapies

Introduction: Many have commented that drug combinations represent the future of NASH therapeutics. As indicated by Pfizer’s recent announcement, large pharma companies are putting efforts toward the...
Learn More

Is Rapid Reversal of Liver Fibrosis Possible?

Title: Is Rapid Reversal of Liver Fibrosis Possible? Author: Peter G. Traber Introduction Treatment of liver fibrosis is a major focus of drug development with multiple companies examining a variety...
Learn More

NASH Cirrhosis Space Poised to Heat Up

Title: NASH Cirrhosis Space Poised to Heat Up Author: Peter G. Traber, MD NASH cirrhosis is the most advanced classification of fibrosis progression in fatty liver disease. Results of clinical trials...
Learn More

Madrigal’s and Viking’s NASH Drugs: Who’s best in class?

Title: Madrigal’s and Viking’s NASH Drugs: Who’s best in class? Author: Peter G. Traber, MD Two companies, Madrigal Pharmaceuticals (NASDAQ: MDGL) and Viking Therapeutics (NASDAQ: VKTX), this year...
Learn More

NASH Bubble?

Title: NASH Bubble? Author: Peter G. Traber, MD Non-alcoholic fatty liver disease (NAFLD) and Non-alcoholic steatohepatitis (NASH) have been the subject of intense interest in the biotech/pharma...
Learn More

Identifying Best Disease Indications for Anti-Fibrotic Drugs

Identifying Best Disease Indications for Anti-Fibrotic Drugs By Peter G. Traber, MD
Learn More

mRNA vaccines: ready for prime time?

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Senolytics- taking aim at ageing cells

by Alex Yule, PhD, Associate, Alacrita Consulting
Learn More

Drugs and the human gut microbiome – beyond antibiotics

by Saadia Basharat, PhD, Consultant and Ashley Clark, Consultant Intern at Alacrita
Learn More

How to start a biotech company

How to start a biotech company by Rob Johnson, Managing Partner and Jess Hearn, Consultant, at Alacrita
Learn More
Previous
1 ... 2 3 4 5 6
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.